MEDICAL POLICY – 2.02.24
Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting

BCBSA Ref. Policy: 2.02.24
Effective Date: Aug. 1, 2019
Last Revised: July 25, 2019
Replaces: N/A

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | CODING | RELATED INFORMATION
EVIDENCE REVIEW | REFERENCES | HISTORY

Clicking this icon returns you to the hyperlinks menu above.

Introduction

Hemodynamic monitoring measures blood pressure inside the heart, veins, and arteries. It’s often done in a hospital for patients with acute heart failure. Implantable hemodynamic monitoring devices have been developed for outpatient use. The device measures the pressure of the pulmonary artery (which transports blood from the heart to the lungs) and the heart rate. The data is transmitted through a computerized system to the patient’s doctor. The goal of the device is to try to see the early signs of acute heart failure and prevent hospitalizations. In the studies published so far, there is limited data about safety and no demonstration that the devices save more lives. There are also unanswered questions about whether these devices reduce hospitalization. For these reasons, implantable hemodynamic monitoring devices are considered investigational (unproven).

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
Policy Coverage Criteria

Service | Investigational
---|---
Cardiac hemodynamic monitoring | In the ambulatory care and outpatient setting, cardiac hemodynamic monitoring for the management of heart failure using any of the following devices is considered investigational:
- Arterial pressure during the Valsalva maneuver
- Implantable direct pressure monitoring of the pulmonary artery (this includes the implantation of the device, eg, CardioMEMS device)
- Inert gas rebreathing
- Thoracic bioimpedance

Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed</td>
</tr>
<tr>
<td>33289</td>
<td>Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>93264</td>
<td>Bioimpedance-derived physiologic cardiovascular analysis</td>
</tr>
<tr>
<td>93701</td>
<td>Unlisted cardiovascular service or procedure</td>
</tr>
</tbody>
</table>
| 93799 | Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).
This policy refers only to the use of stand-alone cardiac output measurement devices designed for use in ambulatory care and outpatient settings. The use of cardiac hemodynamic monitors or intrathoracic fluid monitors that are integrated into other implantable cardiac devices, including implantable cardioverter defibrillators, cardiac resynchronization therapy devices, and cardiac pacing devices are not addressed in this policy.

Evidence Review

Description

A variety of outpatient cardiac hemodynamic monitoring devices are intended to improve quality of life and reduce morbidity for patients with heart failure by decreasing episodes of acute decompensation. Monitors can identify physiologic changes that precede clinical symptoms and thus allow preventive intervention. These devices operate through various mechanisms, including implantable pressure sensors, thoracic bioimpedance measurement, inert gas rebreathing, and estimation of left ventricular end-diastolic pressure by arterial pressure during the Valsalva maneuver.

Background

Chronic Heart Failure

Patients with chronic heart failure are at risk of developing acute decompensated heart failure, often requiring hospital admission. Patients with a history of acute decompensation have the additional risk of future episodes of decompensation and death. Reasons for the transition from a stable, chronic state to an acute, decompensated state include disease progression, as well as acute events such as coronary ischemia and dysrythmias. While precipitating factors are frequently not identified, the most common preventable cause is noncompliance with medication and dietary regimens.\(^1\)
Management

Strategies for reducing decompensation, and thus the need for hospitalization, are aimed at early identification of patients at risk for imminent decompensation. Programs for early identification of heart failure are characterized by frequent contact with patients to review signs and symptoms with a health care provider, education, and medication adjustments as appropriate. These encounters may occur face-to-face in the office or at home, or via cellular or computed technology.2

Precise measurement of cardiac hemodynamics is often employed in the intensive care setting to carefully manage fluid status in acutely decompensated heart failure. Transthoracic echocardiography, transesophageal echocardiography, and Doppler ultrasound are noninvasive methods for monitoring cardiac output on an intermittent basis for the more stable patient but are not addressed herein. A variety of biomarkers and radiologic techniques may be used for dyspnea when the diagnosis of acute decompensated heart failure is uncertain.

The criterion standard for hemodynamic monitoring is pulmonary artery catheters and central venous pressure catheters. However, they are invasive, inaccurate, and inconsistent in predicting fluid responsiveness. Several studies have demonstrated that catheters fail to improve outcomes in critically ill patients and may be associated with harm. To overcome these limitations, multiple techniques and devices have been developed that use complex imaging technology and computer algorithms to estimate fluid responsiveness, volume status, cardiac output and tissue perfusion. Many are intended for use in outpatient settings but can be used in the emergency department, intensive care unit, and operating room. Four methods are reviewed here: implantable pressure monitoring devices, thoracic bioimpedance, inert gas rebreathing, and arterial waveform during the Valsalva maneuver. Use of the last three is not widespread because of several limitations including use of proprietary technology making it difficult to confirm their validity and lack of large randomized controlled trials (RCTs) to evaluate treatment decisions guided by these hemodynamic monitors.

Summary of Evidence

For individuals who have heart failure in outpatient settings who receive hemodynamic monitoring with an implantable pulmonary artery pressure sensor device, the evidence includes RCTs. The relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbid events, hospitalizations, and treatment-related morbidity. One implantable pressure monitor, the CardioMEMS device, has U.S. Food and Drug Administration (FDA) approval. The pivotal CHAMPION RCT reported a statistically significant decrease in heart failure-related
hospitalizations in patients implanted with CardioMEMS device compared with usual care. However, trial results were potentially biased in favor of the treatment group due to use of additional nurse communication to enhance protocol compliance with the device. The manufacturer conducted multiple analyses to address potential bias from the nurse interventions. Results were reviewed favorably by the FDA. While these analyses demonstrated the consistency of benefit from the CardioMEMS device, all such analyses have methodologic limitations. Early safety data have been suggestive of a higher rate of procedural complications, particularly related to pulmonary artery injury. Given that the intervention is invasive and intended to be used for a highly prevalent condition, in the light of limited safety data, lack of demonstrable mortality benefit, and pending questions related to its benefit in reducing hospitalizations, the net benefit remains uncertain. Many of these concerns may be clarified by an ongoing postmarketing study that proposes to enroll 1200 patients (at least 35% women) is reported. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have heart failure in outpatient settings who receive hemodynamic monitoring by thoracic impedance, with inert gas rebreathing, or of arterial pressure during the Valsalva maneuver, the evidence includes uncontrolled prospective studies and case series. The relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbid events, hospitalizations, and treatment-related morbidity. There is a lack of RCT evidence evaluating whether the use of these technologies improves health outcomes over standard active management of heart failure patient. The case series have reported physiologic measurement-related outcomes and/or associations between monitoring information and heart failure exacerbations, but do not provide definitive evidence on device efficacy. The evidence is insufficient to determine the effects of the technology on health outcomes.

### Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 1.

### Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02693691</td>
<td>CardioMEMS European Monitoring Study for Heart Failure</td>
<td>239</td>
<td>Dec 2019</td>
</tr>
<tr>
<td>NCT No.</td>
<td>Trial Name</td>
<td>Planned Enrollment</td>
<td>Completion Date</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>NCT02954341</td>
<td>CardioMEMS HF SystemOUS Post Market Study</td>
<td>800</td>
<td>Dec 2022</td>
</tr>
<tr>
<td>NCT03387813</td>
<td>Hemodynamic-GUIDEd Management of Heart Failure</td>
<td>3600</td>
<td>Apr 2023</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01121107</td>
<td>Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study</td>
<td>486</td>
<td>Apr 2015 (completed)</td>
</tr>
<tr>
<td>NCT00409916a</td>
<td>Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF): Device BioZ Dx</td>
<td>500</td>
<td>Dec 2012 (unknown)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

*a Denotes industry-sponsored or cosponsored trial.

### Practice Guidelines and Position Statements

**American College of Cardiology et al**

The joint guidelines from the American College of Cardiology, American Heart Association, and Heart Failure Society of America (2017) on the management of heart failure offered no recommendations for the use of ambulatory monitoring devices.23

**European Society of Cardiology**

The European Society of Cardiology guidelines on the diagnosis and treatment of acute and chronic heart failure stated the following: “Monitoring of pulmonary artery pressures using a wireless implantable hemodynamic monitoring system (CardioMEMS) may be considered in symptomatic patients with heart failure with previous heart failure hospitalization in order to reduce the risk of recurrent heart failure hospitalization (Class IIb Level B recommendation).”23

**National Institute for Health and Care Excellence**

The updated guidance from the National Institute for Health and Care Excellence (2018) on chronic heart failure management did not include outpatient hemodynamic monitoring as a recommendation.24
The Institute (2013) issued guidance on the insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure.\textsuperscript{25} The recommendations concluded that “Current evidence on the safety and efficacy of the insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure is limited in both quality and quantity.”

\textbf{Heart Failure Society of America}

The Heart Failure Society of America Scientific Statements Committee (2018) published a white paper consensus statement on remote monitoring of patients with heart failure.\textsuperscript{26}

The committee concluded that: "Based on available evidence, routine use of external RPM devices is not recommended. Implanted devices that monitor pulmonary arterial pressure and/or other parameters may be beneficial in selected patients or when used in structured programs, but the value of these devices in routine care requires further study."

\textbf{Medicare National Coverage}

The Centers for Medicare & Medicaid Services (2014) updated its 2006 decision memorandum on thoracic electrical bioimpedance.\textsuperscript{27} Medicare’s national coverage determination found thoracic bioimpedance to be reasonable and necessary for the following indications:

1. Differentiation of cardiogenic from pulmonary causes of acute dyspnea;
2. Optimization of atrioventricular interval for patients with atrioventricular sequential cardiac pacemakers;
3. Monitoring of continuous inotropic therapy for patients with terminal heart failure;
4. Evaluation for rejection in patients with a heart transplant as a predetermined alternative to myocardial biopsy; and

While Medicare permits coverage of thoracic bioimpedance in these conditions, it has acknowledged that there is a “…general absence of studies evaluating the impact of using thoracic bioimpedance for managing patients with cardiac disease....” Medicare does not cover the use of thoracic bioimpedance in the management of hypertension due to inadequate evidence.
Medicare has also specified that thoracic bioimpedance is not covered for “the management of all forms of hypertension (with the exception of drug-resistant hypertension...).” Further, Medicare specified that:

[Contractors] have discretion to determine whether the use of TEB [thoracic bioimpedance] for the management of drug-resistant hypertension is reasonable and necessary. Drug resistant hypertension is defined as failure to achieve goal blood pressure in patients who are adhering to full doses of an appropriate 3-drug regimen that includes a diuretic.

There is no Medicare national coverage determination on implantable direct pressure monitoring, inert gas rebreathing, and arterial pressure with Valsalva.

Effective April 7, 2016, Novitas Solutions issued a noncoverage local coverage determination (ID L36419) for outpatient wireless pulmonary artery pressure monitoring for heart failure (CardioMEMS).

Regulatory Status

Noninvasive Left Ventricular End-Diastolic Pressure Measurement Devices

In 2004, the VeriCor® (CVP Diagnostics), a noninvasive left ventricular end-diastolic pressure measurement device, was cleared for marketing by FDA through the 510(k) process. The FDA determined that this device was substantially equivalent to existing devices for the following indication:

The VeriCor is indicated for use in estimating non-invasively, left ventricular end-diastolic pressure (LVEDP). This estimate, when used along with clinical signs and symptoms and other patient test results, including weights on a daily basis, can aid the clinician in the selection of further diagnostic tests in the process of reaching a diagnosis and formulating a therapeutic plan when abnormalities of intravascular volume are suspected. The device has been clinically validated in males only. Use of the device in females has not been investigated.

FDA product code: DXN
**Thoracic Bioimpedance Devices**

Multiple thoracic impedance measurement devices that do not require invasive placement have been cleared for marketing by the FDA through the 510(k) process. The FDA determined that this device was substantially equivalent to existing devices used for peripheral blood flow monitoring. Table 2 presents an inexhaustive list of representative devices.

FDA product code: DSB

Table 2. Noninvasive Thoracic Impedance Plethysmography Devices

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Clearance Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>BioZ® Thoracic Impedance Plethysmograph</td>
<td>SonoSite</td>
<td>2009</td>
</tr>
<tr>
<td>Zoe® Fluid Status Monitor</td>
<td>Noninvasive Medical Technologies</td>
<td>2004</td>
</tr>
<tr>
<td>Cheetah Starling SV</td>
<td>Cheetah Medical</td>
<td>2008</td>
</tr>
<tr>
<td>PhysioFlow® Signal Morphology-based Impedance Cardiography (SM-ICG™)</td>
<td>Vasocom, now NeuMeDx</td>
<td>2008</td>
</tr>
<tr>
<td>ReDS™ Wearable System</td>
<td>Sensible Medical Innovations</td>
<td>2015</td>
</tr>
</tbody>
</table>

Also, several manufacturers market thoracic impedance measurement devices integrated into implantable cardiac pacemakers, cardioverter defibrillator devices, and cardiac resynchronization therapy devices.

**Inert Gas Rebreathing Devices**

In 2006, the Innocor® (Innovision), an inert gas rebreathing device, was cleared for marketing by FDA through the 510(k) process. The FDA determined that this device was substantially equivalent to existing inert gas rebreathing devices for use in computing blood flow. FDA product code: BZG.

**Implantable Pulmonary Artery Pressure Sensor Devices**

In 2014, the CardioMEMSTM Champion Heart Failure Monitoring System (CardioMEMS, now Abbott) was cleared for marketing by the FDA through the premarket approval process. This
device consists of an implantable pulmonary artery (PA) sensor, which is implanted in the distal PA, a transvenous delivery system, and an electronic sensor that processes signals from the implantable PA sensor and transmits PA pressure measurements to a secure database. The device originally underwent FDA review in 2011, at which point FDA found no reasonable assurance that the monitoring system would be effective, particularly in certain subpopulations, although FDA agreed this monitoring system was safe for use in the indicated patient population.

Several other devices that monitor cardiac output by measuring pressure changes in the PA or right ventricular outflow tract have been investigated in the research setting but have not received FDA approval. They include the Chronicle® implantable continuous hemodynamic monitoring device (Medtronic), which includes a sensor implanted in the right ventricular outflow tract, and the ImPressure® device (Remon Medical Technologies), which includes a sensor implanted in the PA.

Note: This policy only addresses the use of these technologies in ambulatory care and outpatient settings.

References


### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/18</td>
<td>New policy, approved July 10, 2018, effective November 2, 2018. Add to Cardiology section. This policy was previously archived, but it is now being reinstated. Literature review through March 2018. Policy statement: cardiac hemodynamic monitoring for the management of heart failure in the outpatient setting using any of the stated devices is considered investigational.</td>
</tr>
<tr>
<td>01/01/19</td>
<td>Interim Review, approved December 19, 2018. Clarified that implantable direct pressure monitoring of the pulmonary artery includes the implantation of the device as well. Added CPT code 33289 and 93264.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2019 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
- Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5592. TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
- U.S. Department of Health and Human Services
200 Independence Avenue SW, Room S9FF, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost.

Call 800-722-1471 (TTY: 800-842-5357).

Oromo (Cushite):
Lakkoofsa biiblaataa 800-722-1471 (TTY: 800-842-5357) ti biiblaataa.

French (French):
Appelez le 800-722-1471 (TTY: 800-842-5357).

Deutsche (German):

Hmoob (Hmong):

Iloklo (Ilocano):
Daytoy a Pakdaara ket naglaon iti Napateg nga Impomara. Daytoy a pakdaara mabalin nga adda ket naglaon iti napateg nga impomarsa mayanggep iti aplikasanyo nyo coverage babaen ti Premera Blue Cross. Daytoy ket mabalin dagiti importante a pelta iti daytoy a pakdaara. Mabalil nga adda rumbeng nga aramidenyo nga adda sikkay dagiti partikular a naituding nga adaw tapno mapagtalaidayyo ti coverage nga salun-atyo nga tungon kadagiti gastos. Adda karbenganyo a mangala nga daytoy nga impomarsa ken tungon iti bukado nga pagsasao nga awan ti bayadanyo. Tumawag ti numero nga 800-722-1471 (TTY: 800-842-5357).

Italiano (Italian):
This notification contains important information. It is possible that this notification contains important information that you may need to know before certain deadlines. You may wish to contact Premera Blue Cross for more information. 800-722-1471 (TTY: 800-842-5357)